Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1352-1361

  Kim, Karam ^a   Kim, Garam ^a   Kim, Jin Young ^a   Yun, Hyo Jeong ^a   Lim, Sung Chul ^b   Choi, Hong Seok ^a  

^a Chosun University   (South Korea)

^b Chosun University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR 1; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDYLPROLYL ISOMERASE PIN1; RECOMBINANT CYTOKINE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TKI; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; ONCOPROTEIN; PEPTIDYLPROLYL ISOMERASE; PROTEIN C JUN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE ASSAY; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FEMALE; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; ANIMAL; BREAST TUMOR; CELL LINE; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INTERLEUKINS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDYLPROLYL ISOMERASE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

EID: 84905381855     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu044     Document Type: Article

References (50)

1. Sonnenberg, G.F. et al. (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol., 12, 383-390.
2. Duhen, T. et al. (2009) Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol., 10, 857-863.
3. Trifari, S. et al. (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol., 10, 864-871.
4. Pestka, S. et al. (2004) Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol., 22, 929-979.
5. Kotenko, S.V. et al. (2001) Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem., 276, 2725-2732.
6. Li, J. et al. (2004) Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2. Int. Immunopharmacol., 4, 693-708.
7. Jiang, R. et al. (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology, 54, 900-909.
8. Xie, M.H. et al. (2000) Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem., 275, 31335-31339.
9. Grivennikov, S.I. et al. (2010) Immunity, inflammation, and cancer. Cell, 140, 883-899.
10. Erny, K.M. et al. (1996) Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene, 13, 2015-2020.
11. Ceci, J.D. et al. (1997) Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev., 11, 688-700.
12. Salmeron, A. et al. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 protooncoprotein, a novel MAP kinase kinase kinase. EMBO J., 15, 817-826.
13. Chiariello, M. et al. (2000) Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol. Cell. Biol., 20, 1747-1758.
14. Patriotis, C. et al. (1994) Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A., 91, 9755-9759.
15. Tsatsanis, C. et al. (1998) The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cell lines. Proc. Natl. Acad. Sci. U. S. A., 95, 3827-3832.
16. Ballester, A. et al. (1997) Cot kinase regulation of IL-2 production in Jurkat T cells. J. Immunol., 159, 1613-1618.
17. Sugimoto, K. et al. (2004) A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J. Clin. Invest., 114, 857-866.
18. Yeh, E.S. et al. (2007) PIN1, the cell cycle and cancer. Nat. Rev. Cancer, 7, 381-388.
19. Jäger, M. et al. (2006) Structure-function-folding relationship in a WW domain. Proc. Natl. Acad. Sci. U. S. A., 103, 10648-10653.
20. Lu, K.P. (2000) Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog. Cell Cycle Res., 4, 83-96.
21. Zheng, H. et al. (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature, 419, 849-853.
22. Fukuchi, M. et al. (2006) Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int. J. Oncol., 29, 329-334.
23. Wulf, G.M. et al. (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J., 20, 3459-3472.
24. Khanal, P. et al. (2010) The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol. Cancer Ther., 9, 606-616.
25. Ryo, A. et al. (2003) Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell, 12, 1413-1426.
26. Lufei, C. et al. (2007) Pin1 is required for the Ser727 phosphorylationdependent Stat3 activity. Oncogene, 26, 7656-7664.
27. Sebolt-Leopold, J.S. et al. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 4, 937-947.
28. Das, S. et al. (2005) Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J. Biol. Chem., 280, 23748-23757.
29. Radaeva, S. et al. (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology, 39, 1332-1342.
30. Namgoong, G.M. et al. (2010) The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J. Biol. Chem., 285, 23829-23841.
31. Eferl, R. et al. (2003) AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer, 3, 859-868.
32. Karin, M. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem., 270, 16483-16486.
33. Qian, L. et al. (2006) A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells. Biochem. Biophys. Res. Commun., 345, 660-668.
34. Uhlen, M. et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol., 28, 1248-1250.
35. Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 5, 263-274.
36. Mueller, M.M. et al. (2004) Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer, 4, 839-849.
37. Joyce, J.A. (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell, 7, 513-520.
38. Kolch, W. (2005) Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol., 6, 827-837.
39. Yoon, S. et al. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24, 21-44.
40. Thompson, N. et al. (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol., 5, 350-356.
41. Harmey, J.H. et al. (2002) Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer, 101, 415-422.
42. Moore, R.J. et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 5, 828-831.
43. Gelin, J. et al. (1991) Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res., 51, 415-421.
44. Dumitru, C.D. et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell, 103, 1071-1083.
45. Mielke, L.A. et al. (2009) Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J. Immunol., 183, 7984-7993.
46. Sourvinos, G. et al. (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene, 18, 4968-4973.
47. Choi, H.S. et al. (2008) Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J., 22, 113-126.
48. Kim, G. et al. (2013) Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis, 34, 341-350.
49. Lu, K.P. et al. (2002) Pinning down proline-directed phosphorylation signaling. Trends Cell Biol., 12, 164-172.
50. Ryo, A. et al. (2003) Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J. Cell Sci., 116(Pt 5), 773-783.